Accedi

Bibliografie tematiche / HIV/Hepatitis C

Indice

Articoli di riviste
Tesi
Libri
Capitoli di libri
Atti di convegni
Rapporti di organizzazioni

Letteratura scientifica selezionata sul tema "HIV/Hepatitis C"

Autore: Grafiati

Pubblicato: 31 agosto 2024

Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili

Scegli il tipo di fonte:

Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "HIV/Hepatitis C".

Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.

Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.

Articoli di riviste sul tema "HIV/Hepatitis C"

1

Crobu, Maria Grazia, Paolo Ravanini, Clotilde Impaloni, Claudia Martello, Olivia Bargiacchi, Christian Di Domenico, Giulia Faolotto et al. "Hepatitis C Virus as a Possible Helper Virus in Human Hepatitis Delta Virus Infection". Viruses 16, n. 6 (20 giugno 2024): 992. http://dx.doi.org/10.3390/v16060992.

Testo completo

Abstract (sommario):

Previous studies reported that the hepatitis C virus (HCV) could help disseminate the hepatitis D virus (HDV) in vivo through the unrelated hepatitis B virus (HBV), but with essentially inconclusive results. To try to shed light on this still-debated topic, 146 anti-HCV-positive subjects (of whom 91 HCV/HIV co-infected, and 43 with prior HCV eradication) were screened for anti-HDV antibodies (anti-HD), after careful selection for negativity to any serologic or virologic marker of current or past HBV infection. One single HCV/HIV co-infected patient (0.7%) tested highly positive for anti-HD, but with no positive HDV-RNA. Her husband, in turn, was a HCV/HIV co-infected subject with a previous contact with HBV. While conducting a thorough review of the relevant literature, the authors attempted to exhaustively describe the medical history of both the anti-HD-positive patient and her partner, believing it to be the key to dissecting the possible complex mechanisms of HDV transmission from one subject to another, and speculating that in the present case, it may have been HCV itself that behaved as an HDV helper virus. In conclusion, this preliminary research, while needing further validation in large prospective studies, provided some further evidence of a role of HCV in HDV dissemination in humans.

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Dickson-Spillmann, Maria, Severin Haug, Ambros Uchtenhagen, Philip Bruggmann e Michael P. Schaub. "Rates of HIV and Hepatitis Infections in Clients Entering Heroin-Assisted Treatment between 2003 and 2013 and Risk Factors for Hepatitis C Infection". European Addiction Research 22, n. 4 (11 dicembre 2015): 181–91. http://dx.doi.org/10.1159/000441973.

Testo completo

Abstract (sommario):

Background/Aims: We report on the rates of hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV) in 1,313 clients entering heroin-assisted treatment (HAT) in Switzerland from 2003 to 2013. We identify predictors of HCV infection. Methods: Data were collected using questionnaires within 2 weeks of clients' first entry into HAT. Prevalence of HAV, HBV, HCV and HIV was calculated using laboratory test results collected at entry or using reports of older test results. Predictors of HCV status were identified through multiple logistic regression analysis. Results: Results show stable rates of HIV-positive clients and decreasing proportions of HAV- and HBV-infected clients. In 2013, there were 12% (n = 8) HIV-, 20% (n = 12) HAV-, 20% (n = 12) HBV- and 52% HCV- (n = 34) positive clients. Vaccination against HAV and HBV had become more frequent. Predictors of positive HCV status included older age, female gender, earlier year of entry, having spent 1 month or more in detention or prison, use of injected heroin and more years of intravenous use. Conclusion: Our results highlight the fact that efforts to prevent and test for infections and to promote vaccination against HAV and HBV in heroin users need to be continued.

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Shrestha, Lok Bahadur, Gopal K. Yadav, Saugat Pradhan, Abhilasha Sharma, Tejendra Pandit, Roshan Chhetry e Basudha Khanal. "Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal". PLOS ONE 17, n. 3 (3 marzo 2022): e0264791. http://dx.doi.org/10.1371/journal.pone.0264791.

Testo completo

Abstract (sommario):

Introduction This study was conducted with an objective to analyze prevalence and risk factors associated with co-infection of hepatitis B virus (HBV) and hepatitis C virus (HCV) in HIV-positive patients with reference to their CD4+ T cell status. Materials and methods HIV-positive patients visiting the HIV clinic for CD4+ T cells testing at B.P. Koirala Institute of Health Sciences were tested for Hepatitis B and Hepatitis C. Data regarding age, gender, mode of HIV transmission, duration of HIV diagnosis, antiretroviral therapy status, antiretroviral therapy duration, hepatitis B or C status, and CD4+ T cells count were collected via face-to-face interview, and hospital records. The data were entered in Microsoft Excel 2019 v16.0 (Microsoft, WA, USA) and statistical analysis was performed by using statistical package for social sciences, IBM SPSS® v21 (IBM, Armonk, New York). Results Out of 474 HIV-positive patients, HIV-HBV, HIV-HCV, and HIV-HBV-HCV co-infections were seen in 2.95% (14/474), 18.14% (86/474), and 2.53% (12/474) respectively. The primary route of infection was intra-venous drug use (IVDU) in those co-infected with HBV only (8, 57.14%), HCV only (46, 53.49%), and both HBV and HCV (8, 66.67%). HIV patients infected via IVDU were 2.40 times more likely to have HIV-HCV co-infection as compared to those infected via sexual route (AOR 2.40, 95% CI: 1.49,3.86). Similarly, HIV patients with CD4+ T cells count less than 350 cells/mm3 were more likely to have HIV-HBV-HCV co-infection as compared to those with CD4 count equal to and more than 350 cells/mm3 (AOR 13.84, 95% CI: 2.90,66.10). Conclusion HIV-positive patients are at high risk of hepatitis B and/or hepatitis C co-infection. Intravenous drug use, and lower CD4+T cells count are the most important risk predictors of co-infection. All HIV-positive patients should be carefully screened with hepatitis B and hepatitis C tests during their follow-up.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Sattarova, Gulsunai. "PREVALENCE AND GENOTYPES OF HEPATITIS B AND C VIRUS AMONG HIV-INFECTED PEOPLE". Alatoo Academic Studies 23, n. 3 (30 settembre 2023): 497–506. http://dx.doi.org/10.17015/aas.2023.233.50.

Testo completo

Abstract (sommario):

Viruses of parenteral hepatitis HBV, HCV and human immunodeficiency (HIV) are characterized by similar transmission routes and risk groups, in which the probability of acquiring two or more of these infections at once is increased. The aim of the research is to study the prevalence and determine the genotypes of hepatitis B and C virus circulating among HIV-infected people. The results of the studies show a high prevalence of HCV markers (HCV – 45% and HBV- 16%) among HIV-infected people. Co-infected patients had high viral replication of HBV (60%) and HCV (62.7%). Аlso by molecular genetic method, HBV DNA was detected among HBsAg negative and HCV RNA in the absence of anti- HCV. Among those co-infected with HIV+HCV, genotype 1b of hepatitis C virus prevailed so the proportion of the total number was 45.7%. Among those co-infected with HIV+HBV, genotype D of the hepatitis B virus prevailed, which amounted to 70%. The genetic diversity of variants of hepatitis B and C viruses among HIV-infected people is similar to the diversity observed in the general population of the republic.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Tserashkou, D. V., V. M. Mitsura, E. V. Voropaev e O. V. Osipkina. "VIRAL COINFECTIONS IN PATIENTS WITH CHRONIC HEPATITIS B: THEIR PREVALENCE AND CLINICAL SIGNIFICANCE". Hepatology and Gastroenterology 4, n. 2 (2020): 171–76. http://dx.doi.org/10.25298/2616-5546-2020-4-2-171-176.

Testo completo

Abstract (sommario):

Background. Hepatitis B virus (HBV) infection remains a global public health problem. Objective – to analyze the prevalence of viral coinfections with human immunodefciency virus (HIV), hepatitis C virus (HCV), hepatitis delta virus (HDV), TT-viruses and SENV in patients with chronic hepatitis B (CHB) and to assess their inﬂuence on liver disease severity. Material and methods. The observational cross-sectional study included 287 patients with chronic hepatitis B virus (HBV) – those with monoinfection and coinfected with HIV, HCV, HDV. Routine hematological and biochemical tests were performed, serum HBV DNA level as well as liver fbrosis stage were measured. Blood samples from 62 patients for Torque teno virus (TTV), Torque teno mini virus, Torque teno midi virus, SENV (D and H genotypes) DNAs were examined by polymerase chain reaction. Results. Among patients with CHB the prevalence of coinfection HBV + HIV is 6.6%, HBV + HCV – 6.3%, HBV + HDV – 3.8% and HBV + HDV + HCV – 1.7%. CHB patients coinfected with HIV, HCV, HDV had more pronounced biochemical differences and higher proportion of liver cirrhosis vs. HBV-monoinfected ones. The detection rate of TT viruses and their various combinations in patients with CHB is 91.9%, SENV – 66.1%. Conclusion. Coinfection with HIV, HCV, HDV in CHB patients is associated with more severe forms of chronic liver disease as compared to HBV-monoinfection. TT viruses and SENV are widespread and don’t affect the severity of liver disease in patients with CHB.

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Suman, Sonu. "Clinical, haematological, and biochemical profile of HIV patient co-infected with hepatitis B and /or C". International Journal of Research in Medical Sciences 8, n. 11 (28 ottobre 2020): 3955. http://dx.doi.org/10.18203/2320-6012.ijrms20204885.

Testo completo

Abstract (sommario):

Background: Human immunodeficiency virus (HIV) positive population is at higher risk of getting infected with hepatitis B virus (HBV) or hepatitis C virus (HCV) or both. Co-infection with HBV/HCV may possibly complicate the clinical course of HIV in infected patients. Aim and objectives of the study were intended to determine clinical, haematological and biochemical profile of HIV patients co infected with hepatitis B and/or C.Methods: All consecutive patients presented with HIV infection who were coinfected with either Hepatitis B, C or both presenting to immunodeficiency or Gastroenterology OPD Base Hospital Delhi, were included in the study. It was a prospective, observational study.Results: HIV impacts the progression of HCV and increases the likelihood of subsequent liver damage as it is apparent in study by significant raised liver enzymes and hypoalbuminemia in HIV-HCV co infection compare to HIV–HBV. Conclusions: These coinfections are more common in younger and lesser educated people. Biochemical parameters could serve as pointers for early detection of liver disease as result of hepatitis co infections in HIV patients. Prompt diagnosis of HCV and HBV co-infection in HIV patients has both individual and public health benefits.

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Seyoum, Eleni, Meaza Demissie, Alemayehu Worku, Andargachew Mulu, Alemseged Abdissa e Yemane Berhane. "HIV, hepatitis B virus, and hepatitis C virus co-infection among HIV positives in antiretroviral treatment program in selected hospitals in Addis Ababa: A retrospective cross-sectional study". PLOS ONE 17, n. 4 (22 aprile 2022): e0267230. http://dx.doi.org/10.1371/journal.pone.0267230.

Testo completo

Abstract (sommario):

Introduction HIV co-infection with hepatitis B (HIV-HBV) and hepatitis C (HIV-HCV) is known to affect treatment outcomes of antiretroviral therapy (ART); however, its magnitude is not well documented. We aimed to determine the magnitude of HIV-HBV and HIV-HCV co-infections simultaneously in people living with HIV (PLHIV) enrolled in ART care in Addis Ababa. Methods We reviewed the medical records of adults ≥15 years who were receiving ART care in three high burden hospitals in Addis Ababa. Baseline clinical and laboratory test results were extracted from medical records. Co-infection was determined based on hepatitis B surface antigen (HBsAg) and hepatitis C virus antibody (anti-HCV) tests obtained from the medical records. A multivariable logistic regression model was used to identify the risk factors for hepatitis B and C co-infections. Results A total of 873 HIV-positive participants were included in this study. The median age of the participants was 37.5 years, and 55.7% were women. Overall, HIV-HBV co-infection was 5.96% (95% CI: 4.56–7.74), and HIV-HCV co-infection was 1.72% (95% CI: 1.03–2.83). The multivariable logistic regression showed that the male sex was the most independent predictor for viral hepatitis B co-infection with an odds ratio of 2.42(95% CI:1.27–4.63). However, HIV-HCV co-infection did not show a significant association in any of the sociodemographic data of the participants. Conclusion HIV co-infection with hepatitis B was moderately high in individuals enrolled in ART care in Addis Ababa. Men had significantly higher HIV-HBV co-infection. HIV co-infection with hepatitis C was relatively low. Strengthening integrated viral hepatitis services with HIV care and treatment services should be emphasized to improve patient care in health facilities.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Riddhi Pradhan, Kirti Hemwani, Vidit Khandelwal, Bamboriya BL, Yogyata Marothi e Varsha Saxena. "A cross-sectional study on co-infection of hepatitis B and hepatitis C among people living with HIV/AIDS from a tertiary care hospital of Central India". Asian Journal of Medical Sciences 14, n. 4 (1 aprile 2023): 61–67. http://dx.doi.org/10.3126/ajms.v14i4.50299.

Testo completo

Abstract (sommario):

Background: Hepatitis B virus (HBV), hepatitis C virus (HCV), and Human immunodeficiency virus (HIV) infections are prevalent throughout the world. HIV infection increases the risk of HBV and HCV liver disease especially when HIV-associated immunodeficiency progresses. Aims and Objectives: This study was carried out with the objectives as follows: Estimation of the prevalence of HIV- Hepatitis co-infection, determine CD4+T lymphocyte count in co-infected patients, identify most common opportunistic infections in HIV – Hepatitis co- infection. Materials and Methods: A hospital-based, prospective, cross-sectional, and observational study was carried among people with confirmed HIV infection. HIV antibody, hepatitis B surface antigen (HBsAg), and HCV antibody tests were done in all patients visiting to integrated counseling and testing center. HIV, HBV, and HCV viral load were done in all serologically confirmed patients. In HBsAg positive patients various markers for hepatitis such as hepatitis B envelop antigen (HBeAg), anti-hepatitis B core antibody (HBcAb), and anti-hepatitis B envelop antibody were also done. Results: Out of 357 people living with HIV/AIDS (PLHA) patients 15/357 (4.20%) were co-infected with HBV, 03/357 (0.84%) were co-infected with HCV. The overall seroprevalence of Hepatitis virus (HBV+HCV) in PLHA patients was found to be 5.04% (18/357). CD4+T lymphocyte count <200 cells/μL was seen in 66/339 (19.4%), 04/15 (26.6%), and 03/03 (100%) patients of HIV mono-infected, HBV co-infected, and in HCV co-infected patients, respectively. HIV Viral load ≤1000 copies/mL was seen in 324 and 15 patients in HIV mono-infected and HIV- hepatitis co-infected patient, respectively. Among PLHA patients who were positive for HBsAg; 46.7% (n=7) patients had HBV viral load >2000 IU/mL. All hepatitis B co-infected patients were positive for HBcAb test; HBeAg was positive in 40% (n=06). All HBeAg positive were having viral load >2000 IU/mL. Conclusion: HIV-infected patients are more prone to hepatitis associated liver diseases and exposure to the HBV infection than the general population.

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Guo, Fuying, e Lingzhou Yang. "Research Progress on HIV/AIDS with Concomitant Hepatitis B Virus and/or Hepatitis C Virus Infection". Infection International 4, n. 1 (1 marzo 2015): 16–20. http://dx.doi.org/10.1515/ii-2017-0099.

Testo completo

Abstract (sommario):

Abstract Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) involve similar transmission routes, namely, blood, sexual contact, and mother-baby contact. Therefore, HIV infection is usually accompanied by HBV and HCV infections. This observation poses a great challenge to the prevention and treatment of HIV/human acquired immunodeficiency syndrome (AIDS) accompanied by HBV and HCV infection. Highly active antiretroviral therapy (HAART) has been extensively applied. Hence, liverrelated diseases have become the main causes of complication and death in HIV-infected individuals. This paper summarizes the current epidemiology, mutual influence, and treatment of HIV/AIDS accompanied by HBV or HCV infection.

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Basimane-Bisimwa, Parvine, Giscard Wilfried Koyaweda, Edgarthe Ngaïganam, Ulrich Vickos, Ornella Anne Demi Sibiro, Brice Martial Yambiyo, Benjamin Seydou Sombié et al. "Seroprevalence and molecular characterization of viral hepatitis and HIV co-infection in the Central African Republic". PLOS ONE 19, n. 5 (9 maggio 2024): e0291155. http://dx.doi.org/10.1371/journal.pone.0291155.

Testo completo

Abstract (sommario):

Background The Central African Republic (CAR) is one of the countries with the highest prevalence of viral hepatitis infection in the world. Coinfection with HIV increases the morbidity and mortality beyond that of mono-infection with either hepatitis or HIV. The present study describes the geographic distribution of viral hepatitis infections and molecular characterization of these viruses in the CAR. Methodology Out of 12,599 persons enrolled during the fourth Multiple Indicator Cluster Survey of 2010 in the CAR, 10,621 Dried Blood Spot (DBS) samples were obtained and stored at -20°C. Of these DBS, 4,317 samples were randomly selected to represent all regions of the CAR. Serological tests for hepatitis B, D, and C viruses were performed using the ELISA technique. Molecular characterization was performed to identify strains. Results Of the 4,317 samples included, 53.2% were from men and 46.8% from women. The HBsAg prevalence among participants was 12.9% and that HBc-Ab was 19.7%. The overall prevalence of HCV was 0.6%. Co-infection of HIV/HBV was 1.1% and that of HBV/HDV was 16.6%. A total of 77 HBV, 6 HIV, and 6 HDV strains were successfully sequenced, with 72 HBV (93.5%) strains belonging to genotype E and 5 (6.5%) strains belonging to genotype D. The 6 HDV strains all belonged to clade 1, while 4 recombinants subtype were identified among the 6 strains of HIV. Conclusion Our study found a high prevalence of HBV, HBV/HDV and HBV/HIV co-infection, but a low prevalence of HCV. CAR remains an area of high HBV endemicity. This study’s data and analyses would be useful for establishing an integrated viral hepatitis and HIV surveillance program in the CAR.

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Tesi sul tema "HIV/Hepatitis C"

1

Mohsen, Abdul Hadi. "The epidemiology of hepatitis C and HCV-HIV coinfection". Thesis, King's College London (University of London), 2005. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.424448.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Falconer, Karolin. "HIV-1/HCV co-infection immunity and viral dynamics /". Stockholm, 2010. http://diss.kib.ki.se/2010/978-91-7409-762-7/.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Yuen, King-tai, e 袁敬弟. "A study of pharmacogenomics for therapeutic and prognostic guidance towards hepatitis C virus (HCV) for patients co-infected with HIV". Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/193555.

Testo completo

Abstract (sommario):

The cost effectiveness of using novel HCV treatment option, telaprevir and boceprevir, should depend on patients’ respond to conventional PEG-INFα and ribavirin therapy. The study of pharmacogenomics, interleukin-28B (IL-28B) polymorphisms, accompanied with the information of HCV genotypes are suggested to have the strongest predictive value of treatment outcomes and prognosis of disease in individuals infected with HCV who are undergoing conventional PEG-INFα and ribavirin therapy. It is extremely valuable in HCV/HIV co-infected patients as these groups of patients require a complex treatment regimen and demonstrate poor sustained viral response (SVR) rate. The development of a fast and promising IL-28B genotyping assay is urgently needed. A total of 47 blood samples randomly selected from HCV and HIV co-infected patients were used in this investigation. The aims of this study are to evaluate and compare the performance of newly developed IL-28B HybProbe real-time PCR assay using LightCycler® system against Sanger Sequencing method in determining IL-28B polymorphisms on rs12979860 and rs8099917 and to estimate the prevalence of IL-28B polymorphisms among HCV/HIV co-infected patients in Hong Kong. In addition, the genotypic distribution of HCV among the same patient group is identified by using in-house Sanger Sequencing method. It was found that the newly developed IL-28B real-time HybProbe assay resulted in 100% concordance with the traditionally used Sanger Sequencing method. The allele frequencies of C and T were 96% and 4% in rs12979860 and T and G were 97% and 3% in rs8099917 respectively. The CC and TT wild type are predominating in rs12979860 and rs8099917 with frequencies of 93.62% and 95.74% respectively. The most favorable compound genotype CC/TT with both homozygous wild types on both SNPs was the most predominant type with a high prevalence of 93.61%. Among all the samples, 50% samples were found to be HCV genotype 1, 41.18% were genotype 6 and 8.82% were genotype 3. A simple and efficient IL-28B real-time HybProbe assay was developed in this study and proved to show excellent performance on IL-28B genotyping although further optimization is suggested before it can be applied in the clinical setting. The favourable wild type genotypes of rs12979860 and rs8099917 accounted for the most predominant genotypes which is similar to other findings obtained from an Asian population. A comparatively high prevalence of HCV genotype 6 was found in the HCV/HIV co-infected group. Future study with the information of treatment outcomes (HCV viral load) can further evaluate the predictive value of IL-28B polymorphisms on SVR in different HCV genotypes.
published_or_final_version
Medical Sciences
Master
Master of Medical Sciences

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Fialho, Renata. "Neuropsychiatric manifestations of hepatitis C treatment in HIV/HCV co-infection". Thesis, University of Sussex, 2017. http://sro.sussex.ac.uk/id/eprint/71260/.

Testo completo

Abstract (sommario):

Hepatitis C (HCV) infection is associated with high rates of mortality and morbidity. Interferon alpha based treatment for HCV offers a good rate of viral clearance, however the associated neuropsychiatric side effects increase the risk of treatment interruption and disease progression. The HIV/HCV coinfection is of particular interest due to association with higher rates of HCV treatment side effects and earlier treatment discontinuation when compared with HCV mono-infection. Therefore, the aim of the thesis was to further explore the effect of coinfection on mood and cognition and how HCV interferon based treatment influences neuropsychiatric side effects in mono and co-infected samples. Firstly a meta-analysis was performed to explore cognitive impairment and depression in HIV HCV co-infection. The results suggested that there was consistent literature indicating that the coinfected group were more cognitively impaired and more likely to be depressed than the HCV and HIV monoinfected groups. Secondly empirical studies were conducted to analyse the profile of depression during interferon-based treatment, and explore potential risk factors, such as gender and immune profile. Co-infected patients appeared less vulnerable to the emergence of depressive symptoms during HCV treatment than HCV mono-infected patients. Additionally, neither female gender nor immune response were associated with increased vulnerability to depression. Finally, a longitudinal study investigating cognitive performance during interferon-based treatment was conducted. A significant effect of treatment on information processing speed level of executive function was observed. Overall the research reported in this thesis further clarifies the nature of interferon induced depression and cognitive effects differences between mono and coinfected groups. Having identified a neurovegetative symptom profile and speed of processing impairment of executive function during HCV treatment, the discussion considers the potential of targeted interventions via psychotropic medication and cognitive interventions to minimise the impact of these treatment effects and optimise outcomes in this clinical group.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Bertol, Bruna Cristina. "Expressão da molécula HLA-G e polimorfismos da região codificadora do gene HLA-G em pacientes infectados pelo vírus da hepatite C (HCV) apresentando ou não a coinfecção pelo vírus da imunodeficiência humana (HIV)". Universidade de São Paulo, 2016. http://www.teses.usp.br/teses/disponiveis/17/17147/tde-10012017-112046/.

Testo completo

Abstract (sommario):

A hepatite C, causada pelo vírus da hepatite C (HCV), afeta milhões de pessoas no mundo. A transmissão do HCV é semelhante ao HIV, justificando a alta taxa de prevalência da coinfecção. Pacientes coinfectados HCV/HIV apresentam maior taxa de progressão da fibrose hepática e da mortalidade, em comparação aos pacientes monoinfectados com HCV. Assim, o estudo de genes e/ou moléculas que controlam a resposta imune é pertinente. No presente estudo, avaliamos o papel do antígeno leucocitário humano G (HLA-G), molécula com reconhecida atividade imunomoduladora, capaz de inibir a ativação das células T e a atividade citotóxica das células Natural Killers (NK) e linfócitos T CD8+, além de induzir a formação células T reguladoras. Nós investigamos 216 pacientes monoinfectados pelo HCV, 135 pacientes coinfectados HCV-HIV e 152 indivíduos não infectados. A variabilidade do gene HLA-G foi avaliada por sequenciamento de Sanger e a expressão hepática da molécula por imunoistoquímica. A expressão de HLA-G foi observada somente no tecido hepático dos pacientes, principalmente nos hepatócitos. O aumento de expressão de HLA-G foi associado com avanço da fibrose e da atividade necroinflamatória no fígado de ambos os grupos de pacientes. Idade igual ou superior a 40 anos e a cor de pele não-branca também foram associados com aumento da expressão hepática da molécula nos pacientes HCV. Outros fatores do hospedeiro analisados como gênero e genótipo do HCV não foram associados com o nível de expressão de HLA-G no fígado. A frequência do alelo HLA-G*01:01:01:01 estava aumentada nos pacientes HCV e do alelo G*01:05N diminuída nos pacientes coinfectados HCV-HIV, porém, não houveram associações significantes entre a variabilidade genética de HLA-G e a expressão hepática de HLA-G. O presente estudo contribui para a ampliar os conhecimentos acerca da participação da molécula HLA-G na hepatite C crônica, associado ou não com infecção pelo HIV.
Hepatitis C, caused by the hepatitis C virus (HCV), affects millions of people worldwide. The transmission of HCV is similar to HIV, which explains the high prevalence of coinfection. HCV-HIV coinfected patients have higher rate of liver fibrosis progression and mortality when compared to HCV monoinfected patients. Thus, the study of genes and/or molecules that control the immune response is relevant. In the present study, we evaluated the role of human leukocyte antigen G (HLA-G), a molecule known by its immunomodulatory activity, which is capable to inhibit T cell activation and cytotoxic activity of natural killer (NK) cells and CD8+ T cells, in addition to inducing the formation of regulatory T cells. We studied 216 HCV patients, 135 HIV-HCV coinfected patients and 152 uninfected individual. The variability of the HLA-G gene was evaluated by Sanger sequencing and the hepatic expression of the molecule by immunohistochemistry. The HLA-G expression was observed only in liver tissue of patients, mainly in hepatocytes. The increased HLA-G expression was associated with increased liver fibrosis and necroinflammatory activity in both groups of patients. The age greater than or equal to 40 years and the non-white skin color were also associated with increased hepatic expression of the molecule in the HCV patients. Other host factors analyzed as gender and HCV genotype were not associated with the level of HLA-G expression in the liver. The frequency of HLA-G*01:01:01:01 allele was increased in HCV patients and G*01:05N decreased in HCV-HIV coinfected patients, however, there was no significant association between the genetic variability of HLA-G and HLA-G liver expression. The present study contributes to expand the knowledge regarding the participation of HLA-G in chronic C hepatitis, associated or not with the HIV infection.

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Souza, Rafael Leme Cardoso. "Avaliação tecnológica do teste molecular (NAT) para HIV, HCV e HBV na triagem de sangue no Brasil". Universidade de São Paulo, 2018. http://www.teses.usp.br/teses/disponiveis/99/99131/tde-09102018-090250/.

Testo completo

Abstract (sommario):

Após anos de debates, o teste de detecção de ácidos nucleicos (NAT) para HIV e HCV na triagem de sangue foi implementado de forma obrigatória no Brasil em 2013, e HBV, em 2016. Um dos motivos citados sobre o atraso em sua implementação foi o custo elevado que seria adicionado à sorologia e, até o momento, uma ampla avaliação econômica em saúde (AES) a respeito de sua eficiência no país não está disponível. Diversos artigos já demonstraram que a razão incremental de custo-utilidade (ICUR) do NAT em relação à sorologia varia de 0,21 a 8,84 milhões de dólares americanos (US$) para cada QALY ganho. Esta grande variação dá-se, principalmente, por diferenças entre a idade média dos receptores de sangue (RS), incidência/prevalência dos vírus entre os doadores de sangue (DS), custo dos testes e tratamentos médicos, cobertura da vacina contra o HBV e sensibilidade do teste utilizado. Assim, faz-se necessária uma avaliação abrangente desta tecnologia e sua efetividade para o cenário brasileiro. Objetivos: Realizar uma revisão sistemática (RevS) de estudos econômicos completos sobre o uso do NAT para HIV, HCV e/ou HBV no mundo; realizar a AES sobre o NAT sob a perspectiva pública brasileira; caracterizar as doações de sangue em janela imunológica no país. Métodos: Metodologia Cochrane de RevS das bases de dados Medline, Embase, LILACS, CRD, BVS ECO, Google Scholar e IDEAS; questionário aplicado aos bancos de sangue e modelo econômico on-line da International Society of Blood Transfusion (ISBT) para cálculo da ICUR do \"NAT em mini-pool de seis amostras individuais\" (MP6) versus \"testes sorológicos\" (SR) no Brasil. Resultados: Quatorze estudos de dezesseis diferentes países foram avaliados. O NAT apresentou a maior relevância nos países de baixa renda, onde há as maiores prevalências e incidências virais, menores taxas de doadores de repetição (DR) e RS mais jovens. A maioria dos estudos concluiu que o NAT, independente do vírus analisado, não é custo-efetivo. As principais diferenças entre as características dos estudos foram relacionadas aos custos médicos e idade dos RS. O maior desvio dos padrões de uma RevS foram: não incluir o racional para definição dos desfechos e o modelo utilizado e não ter claro o conflito de interesse dos autores; para esta AES, o MP6 versus SR apresentou um ICUR de US$ 231.630,00/QALY, ou seja, 26,2 vezes o PIB per capita nacional) e um ICER de US$ 330.790,00/Ano de vida ganho (AVG). A análise de sensibilidade univariada do modelo demonstrou que somente a taxa de desconto, idade do RS, custo do NAT e epidemiologia dos vírus alteraram de forma significativa o ICUR obtido, variando desde US$ 76.957,00/QALY a US$ 933.311,00/QALY; a maioria dos casos de janela imunológica no Brasil são jovens, média de 29 anos, do sexo masculino, com pelo menos o ensino médio completo e mesmo com a obrigatoriedade do Anti-HBc no Brasil, o NAT-HBV é o que apresentou o maior rendimento. Conclusões: Os jovens, principalmente, ainda buscam os bancos de sangue como locais de testagem após comportamento de risco e é de extrema importância a revisão do custo real e completo do teste NAT no Brasil para ampla abordagem da tecnologia nacional incorporada e, se necessário, revisar a forma e modelo de reembolso da mesma e permitir a defesa do bem-estar da população e do bem público.
After years of discussion, nucleic acid (NAT) testing in the blood screening for HIV and HCV was implemented in Brazil in 2013 and HBV in 2016. One of the reasons cited for the delay in its implementation was the high cost that would be added to serology screening and a comprehensive economic assessment of its efficiency in the country is not yet available. Several articles have already shown that the incremental cost-utility ratio (ICUR) of NAT versus serology ranges from 0.21 to 8.84 million American dollars (US$) for each QALY gained. This large variation is mainly due to differences between the mean age of the blood recipient, viruses\' incidence / prevalence among donor population, cost of medical tests and treatments, HBV vaccine coverage, and sensitivity of the test used. Thus, a comprehensive evaluation of this technology and its effectiveness under the perspective of the Brazilian public health system (SUS) is needed. Objectives: Development of a systematic review (RevS) of complete economic studies about the use of NAT for HIV, HCV and / or HBV in the world. Conduct an economic evaluation of NAT under SUS perspective; characterize Brazilian blood donations in the serology \"window period\". Methods: Cochrane RevS Methodology of the Medline, Embase, LILACS, CRD, CRD ECO, Google Scholar and IDEAS databases; Questionnaire applied to blood banks and online economic model from the International Society of Blood Transfusion (ISBT) to calculate the ICUR for \"NAT in mini-pool of six individual samples\" (MP6) versus \"Serology Tests\" (SR) in Brazil. Results: Fourteen studies from sixteen different countries were assessed. NAT was most relevant in low-income countries, where there are the highest prevalences and viral incidences, lower rates of repeat donors and younger recipients of blood (RS). Most of the studies concluded that NAT, regardless of the virus evaluated, is not cost-effective. Differences in the characteristics of the studies were related to the costs and age of RS. The major deviations from RevS standards were: not including the rationale for selecting the outcomes and the model used and not being clear about the authors\' conflict of interest; MP6 vs SR showed an ICUR of US$ 231.630,00/QALY, 26,2 times Brazilian GND per capita) and an ICER of US$ 330.790,00/Life year gained (AVG). The univariate sensitivity analysis of the model demonstrated that only changes on discount rate, NAT cost, RS age and viruses\' epidemiology significantly altered the ICUR in a range between US$ 76.957,00/QALY and US$ 933.311,00/QALY; Most RS window period cases in Brazil are young, average of 29 years old, male, with at least high school education completed and even with the requirement of Anti-HBc in Brazil, NAT-HBV is the one that presented the highest yield. Conclusions: Young people, mainly, still seek blood banks as testing sites, especially after a risk behavior. It is extremely important to reveal the real and complete cost of the Brazilian NAT to fully evaluate its efficiency and, if needed, reassess its current reimbursement model, allowing the wellbeing defense of the population and public interest.

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Del-Rios, Nativa Helena Alves. "Estudo epidemiológico e molecular da infecção pelo vírus da Hepatite C em indivíduos infectados pelo vírus da Imunodeficiência Humana em Goiânia-Goiás". Universidade Federal de Goiás, 2011. http://repositorio.bc.ufg.br/tede/handle/tede/7241.

Testo completo

Abstract (sommario):

Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-04-27T18:05:38Z No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Rejected by Erika Demachki (erikademachki@gmail.com), reason: on 2017-04-27T18:05:52Z (GMT)
Submitted by Erika Demachki (erikademachki@gmail.com) on 2017-04-27T18:06:12Z No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Approved for entry into archive by Luciana Ferreira (lucgeral@gmail.com) on 2017-05-03T11:47:33Z (GMT) No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5)
Made available in DSpace on 2017-05-03T11:47:33Z (GMT). No. of bitstreams: 2 Dissertação - Nativa Helena Alves Del-Rios - 2011.pdf: 2685862 bytes, checksum: a88d60dfeef4b6b920f7a23cc00881a3 (MD5) license_rdf: 0 bytes, checksum: d41d8cd98f00b204e9800998ecf8427e (MD5) Previous issue date: 2011-03-30
Fundação de Amparo à Pesquisa do Estado de Goiás - FAPEG
The hepatitis C virus (HCV) and human immunodeficiency virus (HIV) are characterized by causing chronic infections in the host. The advent of potent antiretroviral therapy has resulted in a significant reduction in the incidence of opportunist infections, and thus greater life expectancy for HIV positive patients. However, the liver disease appears as a major cause of morbidity and mortality among these patients, especially those related to hepatitis C virus. Co-infection with HCV/HIV induces a worse prognosis for both infections, which may lead to the development of AIDS, a faster rapid evolution to chronic active hepatitis and / or liver cirrhosis and death. This study aimed to investigate the epidemiology and molecular profile HCV infection in HIV-infected individuals with no prior antiretroviral therapy, seen in the referral hospital for the treatment of infectious diseases (Hospital for Tropical Diseases - Anuar Auad / HDT) in Goiania, Goiás. A total of 505 treatment naïve individuals and were referred to the HDT, from April 2009 to April 2010 were interviewed and underwent blood collection. All sera were tested for antibodies to HCV (anti-HCV) and for HCV RNA by polymerase chain reaction (PCR). Genotyping was performed by reverse hybridization by the Line Probe Assay (LiPA) method. The prevalence of anti-HCV was 4.6% (95% CI: 3.0 to 6.8). The viral RNA was detected in 65.2% (15/23) of anti-HCV positive samples. The genotypes identified were 1 (subtypes 1a and 1b) and 3 (subtype 3a). The age > 40 years, living in other states or Goiania city, surgery, injecting and non-injecting drug and anti-HBc positive (antibody to core antigen of hepatitis B virus) were associated with HCV infection after logistic regression. The data presented shows the vulnerability of the HIV sropositive population to acquisition of infectious diseases such as HCV infection. Thus, the information obtained will be essential for planning public health interventions, preventing and control of hepatitis C in this population.
Os vírus da hepatite C (HCV) e da imunodeficiência humana (HIV) causam infecções crônicas no hospedeiro. O advento da terapia antiretroviral potente trouxe uma redução da incidência de infecções oportunistas, e consequentemente, uma maior expectativa de vida aos pacientes HIV soropositivos. No entanto, as hepatopatias surgem como uma das principais causas de morbimortalidade entre esses pacientes, principalmente aquelas relacionadas ao vírus C. A coinfecção HCV/HIV induz a um pior prognóstico de ambas as infecções, podendo levar ao desenvolvimento da Aids, evolução mais rápida para hepatite crônica ativa e/ou cirrose hepática e morte. Este estudo teve como objetivo investigar o perfil epidemiológico e molecular da infecção pelo HCV em indivíduos infectados pelo HIV, sem tratamento antiretroviral prévio, atendidos no Hospital de referência para o tratamento de doenças infecciosas (Hospital de Doenças Tropicais - Anuar Auad / HDT) em Goiânia, Goiás. Um total de 505 indivíduos, virgens de tratamento, encaminhados ao HDT, no período de abril/2009 a abril/2010, foram entrevistados e submetidos à coleta de sangue. As amostras (soros) foram testadas para a detecção de anticorpos para o HCV (ELISA/LIA) e submetidas à identificação do RNA-HCV pela reação em cadeia da polimerase (PCR). A genotipagem foi realizada por hibridização reversa, pelo método Line Probe Assay (LiPA). A prevalência para anti-HCV foi de 4,6% (IC 95%: 3,0-6,8). O RNA viral foi detectado em 15 amostras, sendo todas elas anti-HCV positivas. Foram identificados os genótipos 1 e 3, com predomínio do subtipo 1a, seguido dos subtipos 1b e 3a. As variáveis idade superior a 40 anos, ser procedente de Goiânia ou outros estados, cirurgia, uso de drogas injetáveis e não-injetáveis, história de prisão e positividade ao anti-HBc foram associados à infecção pelo vírus da hepatite C, após regressão logística. Os dados apresentados revelam a vulnerabilidade da população HIV soropositiva à aquisição de doenças infecciosas como a infecção pelo HCV. Assim, as informações obtidas serão essenciais para o planejamento de ações de saúde pública para a prevenção e controle da hepatite C nessa população.

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Gröner, Jan Benedikt. "Mitochondriale Dysfunktion bei chronischer Hepatitis B, chronischer Hepatitis C und bei HIV-Postexpositionsprophylaxe". Diss., lmu, 2011. http://nbn-resolving.de/urn:nbn:de:bvb:19-135665.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Barbosa, Alexandre Naime [UNESP]. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C". Universidade Estadual Paulista (UNESP), 2010. http://hdl.handle.net/11449/101466.

Testo completo

Abstract (sommario):

Made available in DSpace on 2014-06-11T19:31:28Z (GMT). No. of bitstreams: 0 Previous issue date: 2010-06-18Bitstream added on 2014-06-13T18:42:08Z : No. of bitstreams: 1 barbosa_an_dr_botfm.pdf: 1241955 bytes, checksum: 4ebec113ac46c15142666ca4f710746d (MD5)
Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES)
Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
Universidade Estadual Paulista (UNESP)
A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico...
Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Barbosa, Alexandre Naime. "Avaliação das citocinas (ELISA e RT-PCR) e da fibrose hepática na coinfecção pelo HIV e vírus da hepatite C /". Botucatu : [s.n.], 2010. http://hdl.handle.net/11449/101466.

Testo completo

Abstract (sommario):

Orientador: Domingues Alves Meira
Banca: Alexandrina Sartori
Banca: Ricardo Sobhie Diaz
Banca: Fernando Lopes Gonçalves Júnior
Resumo: A aids e a hepatite C crônica são infecções caracterizadas por importante processo inflamatório contínuo, regulado por uma complexa interação entre citocinas. A persistência da atividade inflamatória crônica está intimamente relacionada com a progressão da patogênese da aids, bem como na indução de fibrose na hepatite C. Com o objetivo de avaliar o padrão de citocinas na infecção pelo HIV e na hepatite C crônica, as citocinas IL-2, IL-4, IL-10, TNF-α, INF-γ, TGF-β foram dosadas por Elisa e RT-PCR em cinco grupos: pacientes coinfectados pelo HIV/VHC (n=22), monoinfectados pelo HIV com supressão virológica pelo tratamento, e sem supressão virológica (n=17), monoinfectados pelo VHC (n=22) e um grupo controle composto por indivíduos doadores de sangue (n=10). IL-4 e IL-10 estiveram aumentadas consistentemente nos quatro grupos de estudo, determinando predomínio do perfil Th-2. INF-γ, TNF-α e TGF-β estiveram aumentados apenas nos grupos com infecção pelo VHC, com ou sem coinfecção pelo HIV. No grupo de monoinfectados pelo HIV com supressão virológica, a IL-2 dosada por RT-RCR esteve aumentada, porém os níveis séricos dosados por Elisa estavam normais. A alta produção de citocinas pró-inflamatórias INF-γ, TNF-α e TGF-β nos dois grupos de pacientes com infecção pelo VHC refletem o processo progressivo de acúmulo de inflamação e fibrose hepática. Já o predomínio de IL-4 e IL-10 em todos os grupos, citocinas ligadas ao perfil Th-2, demonstram a incapacidade de produção de uma resposta citotóxica Th-1, perpetuando a infecção e a inflamação crônica, mesmo naqueles indivíduos com supressão virológica pelo tratamento. Além de drogas antivirais, novos tratamentos imunomoduladores têm sido propostos para a erradicação viral, ou a interrupção das lesões causadas pelo estado inflamatório crônico... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: Both AIDS and chronic hepatitis C (HCV) are characterized by continuous inflammatory process, regulated by a complex interaction between cytokines. The persistence of chronic inflammatory activity is closely related to the progression of the pathogenesis of AIDS, as well as the induction of fibrosis in HCV. In order to analyze the role of cytokines in HIV/HCV coinfection and the fibrosis progression, IL-2, IL-4, IL-10, TNF- α, INF-γ, TGF-β were measured by ELISA and RT -PCR in five groups: HIV/HCV coinfected patients (n = 22), HCV monoinfected patients (n = 22), HIV monoinfected patients with and without virological suppression (n = 17) and a control group composed by blood donors (n = 10). Hepatic biopsy and METAVIR classification were performed in all HCV patients (n=44). The baseline characteristics (sex, age and race) of all groups were similar. No correlations were found between cytokines and hepatic fibrosis. IL-4 and IL-10 were consistently increased in the four study groups, findings associated to a Th-2 profile. INF- γ, TNF-α and TGF-β were increased only in groups with HCV infection. In the group of HIV monoinfected patients with virological suppression, IL-2 measured by RT-RCR was increased, but serum levels measured by ELISA were normal. The high production of proinflammatory cytokines INF-γ, TNF-α and TGF-β in two groups of patients with HCV infection reflect the gradual process of inflammation and liver fibrosis. The predominance of IL-4 and IL-10 in all study groups demonstrates an inability to promote a cytotoxic Th-1 response. Even in HIV monoinfected patients with virological suppression with increased IL-2 expression, Th-2 cytokines were the predominant, perpetuating the chronic inflammation. In addition to antiviral drugs, new immunomodulatory treatments have been proposed... (Complete abstract click electronic access below)
Doutor

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Libri sul tema "HIV/Hepatitis C"

1

Ireland. Hepatitis C Compensation Tribunal. Annual report of the Hepatitis C Compensation Tribunal. Dublin: Stationery Office, 2003.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Saskatchewan Subcommittee on HIV/AIDS. Guidelines for the management of potential exposures to Hepatitis B, Hepatitis C, HIV, and recommendations for post-exposure prophyalxis. Saskatchewan: Saskatchewan Health, 2004.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Dublin, Ireland. Minister for Justice, Equality, and Law Reform. e Trinity College (Dublin, Ireland). Dept. of Community Health and General Practice., a cura di. Hepatitis B, hepatitis C and HIV in Irish prisoners: Prevalence and risk. Dublin: Stationery Office, 1999.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Musharraf, Husain, e Population Council (Bangladesh), a cura di. Prevalence of HIV, HBV, HCV and syphilis markers in pregnant women of Bangladesh. Dhaka, Bangladesh: Population Council, 1997.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

San Francisco (Calif.). Dept. of Public Health. Communicable Disease Control Unit. Registry match: Chronic hepatitis B, hepatitis C infection and HIV : 2010, San Francisco, California. San Francisco, Calif: San Francisco Department of Public Health, 2011.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Association, American Nurses. HIV, Hepatitis-B, Hepatitis-C: Blood-borne diseases; nurses' risks, rights, and responsibilities. Washington, DC: ANA, 1993.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Dias, Giselle. Hard time: HIV and hepatitis C prevention programming for prisoners in Canada. Toronto: Canadian HIV/AIDS Legal Network = Râeseau juridique canadien VIH/Sida, 2007.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Thiemann, Lillian. Double jeopardy: The HIV/HCV co-infection handbook. New York: Community Prescription Service, 1999.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Ruiz, Juan D. Seroprevalence of HIV, hepatitis B, hepatitis C, and risk behaviors among inmates entering the California correctional system. [Sacramento]: California Dept. of Health Services, Office of Aids, HIV/AIDS Epidemiology Branch, 1996.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Report of the Tribunal of Inquiry into the Infection with HIV and Hepatitis C of Persons with Haemophilia and Related Matters. Dublin: Stationery Office, 2002.

Cerca il testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Più fonti

Capitoli di libri sul tema "HIV/Hepatitis C"

1

Salmon-Ceron, Dominique, J. E. Arends, C. Leoni, C. Solas e G. Peytavin. "HIV/HCV Coinfection: Current Challenges". In Viral Hepatitis: Chronic Hepatitis C, 141–57. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-03757-4_7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Ingiliz, Patrick, Maud Lemoine e Yves Benhamou. "Chronic HCV and HIV Coinfection". In Chronic Hepatitis C Virus, 75–91. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4614-1192-5_7.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Sulkowski, Mark S. "Hepatitis C: Natural History". In HIV and Liver Disease, 101–5. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1712-6_11.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Matthews, Gail V., e Gregory J. Dore. "HIV and Hepatitis C Co-Infection". In Advanced Therapy for Hepatitis C, 177–84. Oxford, UK: Wiley-Blackwell, 2011. http://dx.doi.org/10.1002/9781444346343.ch22.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Chung, Raymond, e Gyanprakash Avinash Ketwaroo. "Hepatitis C Virus Treatment in HIV". In HIV and Liver Disease, 133–39. New York, NY: Springer New York, 2011. http://dx.doi.org/10.1007/978-1-4419-1712-6_15.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Carlin, Joseph, Maria Cassia Mendes-Correa e Marina Núñez. "Hepatitis B and C". In Sexually Transmitted Infections in HIV-Infected Adults and Special Populations, 175–89. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-56694-8_10.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Rauch, Andri, e Jürgen Kurt Rockstroh. "Hepatitis C Virus Infection and HIV". In Encyclopedia of AIDS, 1–9. New York, NY: Springer New York, 2015. http://dx.doi.org/10.1007/978-1-4614-9610-6_426-1.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Pandya, Shuchi, Misbahuddin Syed, Manuel Castro, Jamie P. Morano e Beata Casanas. "Hepatitis C and HIV Neurological Implications". In Global Virology II - HIV and NeuroAIDS, 625–43. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7290-6_24.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Rauch, Andri, e Jürgen Kurt Rockstroh. "Hepatitis C Virus Infection and HIV". In Encyclopedia of AIDS, 625–33. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7101-5_426.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Presterl, Elisabeth, Magda Diab-El Schahawi, Luigi Segagni Lusignani, Helga Paula e Jacqui S. Reilly. "Blood-Borne Viruses: HIV, Hepatitis B, and Hepatitis C". In Basic Microbiology and Infection Control for Midwives, 143–49. Cham: Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-030-02026-2_15.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Atti di convegni sul tema "HIV/Hepatitis C"

1

Paschoini, MC, LN Resende, MM Mendonça, GPM Gomide e JU Ribeiro. "P3.181 Hepatitis c: challenging modern obstetrics". In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.416.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Schmidt, Axel. "S03.4 Hepatitis C in HIV-negative MSM – a growing concern?" In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.27.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Brieva Herrero, MT, I. Reyes Torres, M. Sáez-Torres de Vicente, P. López López, M. Frias Casas e A. Rivero Juárez. "4CPS-267 Lack of hepatitis C virus uptake in HIV/HCV co-infected patients". In 24th EAHP Congress, 27th–29th March 2019, Barcelona, Spain. British Medical Journal Publishing Group, 2019. http://dx.doi.org/10.1136/ejhpharm-2019-eahpconf.416.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Santos, Alaides de Abreu, Talia Hahn Augusto, Geovane Barbosa da Silva, Tatiana Mugnol, Luiza Mariana Alvarez Elicker, Taila Brant, Ana Lidia Toebe, Kelly Silva Rodrigues, Janaina Coser e Janice de Fátima Pavan Zanella. "Vírus da hepatite C em pacientes hemodialisados: uma breve revisão". In XIII Congresso da Sociedade Brasileira de DST - IX Congresso Brasileiro de AIDS - IV Congresso Latino Americano de IST/HIV/AIDS. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/dst-2177-8264-202133p250.

Testo completo

Abstract (sommario):

Introdução: A hepatite C é um problema de saúde pública, com maior prevalência em pacientes com doença renal crônica. Objetivo: Conhecer a relação do vírus da hepatite C em pacientes hemodialisados. Métodos: Foi realizada uma revisão bibliográfica, com abordagem qualitativa. A busca artigos ocorreu em março de 2019. Foram selecionados artigos no idioma de português e inglês, extraídos de sites de coleção como LILACS, SciELO, PubMed, EBSCO e Ministério da Saúde, no período de 2009-19 e utilizados os seguintes descritores em português: HCV, hepatite C, hemodiálise, doença renal, diálise. E, em inglês: hepatitis c, hemodialysis, renal disease, dialysis. Ao todo, neste estudo foram incluídos oito artigos. Resultados: A hepatite C é causada por um vírus com genoma de fita simples ácido ribonucleico, envelopado, com um diâmetro que varia de 55 a 65 nm, da família Flaviviridae, do gênero Hepacivirus. O Brasil registrou 24.460 casos de hepatite C em 2017, sendo Porto Alegre (RS) a capital com as maiores taxas (90,7 casos/100 mil habitantes). A proporção de infecções por via sexual foi de 9,2%, relacionadas ao uso de drogas, 8,1%, e as infecções por via transfusional, 6,8%. Pacientes com a doença renal crônica são predispostos a contaminação pelo vírus. As principais formas de contágio de pacientes em hemodiálise têm sido as diversas transfusões sanguíneas, resultados falso-negativos, fazendo uma disseminação por equipamento, objetos compartilhados pelos pacientes e quebra de biossegurança dos próprios profissionais. O teste de hepatite C deve ser feito em todos os pacientes que iniciarem o programa de hemodiálise, com confirmação utilizando-se os testes moleculares. Conclusão: A infecção em pacientes com doença renal crônica em hemodiálise vem aumentando ao longo do tempo. Fazem-se necessários maiores cuidado e prevenção nos centros de hemodiálise para que haja redução da contaminação pelo vírus da hepatite C em pacientes com doença renal crônica.

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Mckee, Geoff, Nuria Chapinal, Zahid Butt, Carmine Rossi, Stanley Wong, Mark Gilbert, Jason Wong et al. "P388 Evolution of hepatitis C care cascades among HIV and hepatitis B co-infected patients in british columbia, canada". In Abstracts for the STI & HIV World Congress (Joint Meeting of the 23rd ISSTDR and 20th IUSTI), July 14–17, 2019, Vancouver, Canada. BMJ Publishing Group Ltd, 2019. http://dx.doi.org/10.1136/sextrans-2019-sti.483.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

6

Rey, MB Contreras, J. Estaire Gutiérrez, R. Sánchez del Moral, MM Romero Alonso, MA Bolivar Raya e C. Bocanegra Martín. "5PSQ-046 Direct-acting antivirals for hepatitis c virus in hiv co-infected patients". In Abstract Book, 23rd EAHP Congress, 21st–23rd March 2018, Gothenburg, Sweden. British Medical Journal Publishing Group, 2018. http://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.400.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

7

Prasad, Yash, Khine Phyu, Lee Parker, Mark Aldersley e Emma Page. "P63 ‘Get tested LeEDs’: testing for hepatitis B, hepatitis C and HIV in an Urban emergency department via notional consent". In BASL Abstracts, 21–23 September, 2020. BMJ Publishing Group Ltd and British Society of Gastroenterology, 2020. http://dx.doi.org/10.1136/gutjnl-2020-basl.73.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

8

Ronchi, Bruna Ribas, Gabriela Marçal Rios, Rosalie Kupka Knoll e Carolina Cardoso. "P3.29 Prevalence of hiv, sifilis, hepatitis b and hepatitis c in the inmates of the penitentiary complex of vale do itajaÍ-sc". In STI and HIV World Congress Abstracts, July 9–12 2017, Rio de Janeiro, Brazil. BMJ Publishing Group Ltd, 2017. http://dx.doi.org/10.1136/sextrans-2017-053264.266.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

9

Kerschberger, B., N. Ntshalintshali, M. Mafomisa, E. Mabhena, M. Daka, E. Mukooza, SV Dlamini et al. "High burden of sexually transmitted infections and poor diagnostic performance of syndromic approaches within a decentralised HIV care setting in Eswatini". In MSF Scientific Day International 2023. NYC: MSF-USA, 2023. http://dx.doi.org/10.57740/4e0e-e138.

Testo completo

Abstract (sommario):

INTRODUCTION Sexually transmitted infections (STI’s) are a public health threat. Syndromic approaches based on clinical symptoms have been suggested as having poor diagnostic performance, particularly in the type of settings where MSF is operational. We assessed the burden of STI’s and the diagnostic performance of a syndromic approach within an MSF-supported HIV/STI project in Eswatini. METHODS We conducted a cross-sectional study, enrolling adults accessing routine HIV testing and antiretroviral care services in six clinics in Shiselweni, from July 2022 to January 2023. HIV testing counselors performed HIV testing and nurses assessed patients for STI’s. Laboratory investigations included antibody-based rapid diagnostic tests (RDT’s) for Treponema pallidum (TP), hepatitis B (HBV) and hepatitis C (HBC). The molecular platform Xpert was used to test urine samples for Chlamydia trachomatis (CT), Neisseria gonorrhoea (NG), Trichomonas vaginalis (TV), Mycoplasma genitalium (MG), vaginal/anal swabs for human papillomavirus (HPV), and plasma for HIV viraemia to test for acute HIV infection (HIV). We calculated the prevalence of STI’s, and assessed diagnostic performance of a syndromic approach to diagnose male urethritis (MUS) and vaginal discharge (VDS) syndromes, versus laboratory-based testing. ETHICS This study was approved by the Eswatini Health and Human Research Review Board and by the MSF Ethics Review Board. RESULTS Of 1,041 study participants, 682 were women (65.5%), and the median age was 30 (interquartile range, IQR, 24-38) years. Overall, 280 (26.9%) were known HIV-positive and of 755 with unknown HIV status, 30 (4.0%) were newly diagnosed with HIV, of whom seven (23.3%) had AHI. 308 (29.6%) patients had at least one of the following three pathogens identified: NG 121 (11.6%); CT 155 (14.9%); TV 109 (10.5%). MG was detected in 33/330 participants (10.0%). In addition, 105 (10.1%) had antibodies against TP, 49 (4.7%) against HBV, and three (0.3%) against HCV. HPV prevalence was higher in tested women (104/196; 53.1%) versus men (5/27; 18.5%; p=0.001). Prevalence of NG/CT/TP was highest in newly-diagnosed HIV cases (48.2%) versus known HIV-positive cases (26.8%, p=0.019). Based on the syndromic approach, 188/634 (29.7%) had a VDS, and 97/334 (29.0%) a MUS. Diagnostic performance of the syndromic approach was better in men (MUS: sensitivity: 66.7%, specificity 87.5%; positive predictive value, PPV, 70.1%, negative predictive value, NPV, 85.7%), versus women (VDS: sensitivity 35.9%, specificity 72.9%; PPV 35.1%, NPV 73.5%). CONCLUSION A high burden of STI’s in Eswatini and poor diagnostic ability of the syndromic approach in this setting, calls for new approaches for STI care in MSF-supported sexual and reproductive health programmes in resource-poor settings. CONFLICTS OF INTEREST None declared

Gli stili APA, Harvard, Vancouver, ISO e altri

10

Sow, P. "P432 The prevalence of co-infection with HIV, Hepatitis C and TB among patients infected by HIV/AIDS in Senegal". In Abstracts for the STI & HIV World Congress, July 14–17 2021. BMJ Publishing Group Ltd, 2021. http://dx.doi.org/10.1136/sextrans-2021-sti.452.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

Rapporti di organizzazioni sul tema "HIV/Hepatitis C"

1

Goller, Jane, Stephanie Munari, Cassandra Caddy, Teralynn Ludwick, Jacqueline Coombe, Meredith Temple-Smith, Lena Sanci e Jane Hocking. General Practice engagement: STI, HIV and viral hepatitis care. The Sax Institute, giugno 2023. http://dx.doi.org/10.57022/lnur4773.

Testo completo

Abstract (sommario):

Early detection and treatment of sexually transmitted infections, HIV, and hepatitis B and C are vital to minimise the harm they cause. This Evidence Check aimed to identify effective initiatives that engage and support GPs and the GP clinic workforce in NSW to increase testing for these conditions. It also aimed to identify effective modifications to practice management software to increase GP engagement in screening and care for these conditions. Sixty-two articles were found in total. The most effective initiatives used multiple interventions, particularly provider education and quality improvement. They involved both GPs and other health workers, and offered clinic-level initiatives to help identify patients at higher risk (e.g. software-generated alerts) and engage them in testing (e.g. through self-collected specimens). Models of care that used nurse-led testing or links to specialist services offered a way to increase capacity to carry out testing. The quality of evidence was mixed—there were few randomised controlled trials, and little evidence about the sustainability of the initiatives over time, highlighting the need for further high-quality research.

Gli stili APA, Harvard, Vancouver, ISO e altri

2

Buresh, Christopher. The Opioid Epidemic in Iowa and the Connection to Hepatitis C and HIV Outbreaks. Iowa City, Iowa: University of Iowa Public Policy Center, gennaio 2019. http://dx.doi.org/10.17077/rep.001111.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

3

Goldstein, Neal. Epidemiology Blog of Neal D. Goldstein, PhD, MBI. Neal D. Goldstein, 2023. http://dx.doi.org/10.17918/goldsteinepi.

Testo completo

Abstract (sommario):

Musings on topics related to epidemiology, epidemiological methods, public and clinical health. Written by Neal D. Goldstein, PhD, MBI. Dr. Goldstein is an Associate Professor of Epidemiology at the Drexel University Dornsife School of Public Health. With a background in biomedical informatics, he focuses on computational approaches in complex data settings, especially electronic health records and disease surveillance, to understand infectious disease transmission. This has been demonstrated through his work with blood borne pathogens (HIV and hepatitis C), COVID-19, vaccine preventable diseases, and healthcare associated infections.

Gli stili APA, Harvard, Vancouver, ISO e altri

4

Saraswati, Lopamudra, Mary Sebastian, Avina Sarna, Vartika Sharma, Ira Madan, Dean Lewis, Ibou Thior e Waimar Tun. Prevalence of HIV, hepatitis B and C, and co-infection in a cohort of male injection drug users in Delhi. Population Council, 2013. http://dx.doi.org/10.31899/hiv10.1001.

Testo completo

Gli stili APA, Harvard, Vancouver, ISO e altri

5

Mark, Tami L., William N. Dowd e Carol L. Council. Tracking the Quality of Addiction Treatment Over Time and Across States: Using the Federal Government’s “Signs” of Higher Quality. RTI Press, luglio 2020. http://dx.doi.org/10.3768/rtipress.2020.rr.0040.2007.

Testo completo

Abstract (sommario):

The objective of this study was to track trends in the signs of higher-quality addiction treatment as defined by the National Institute on Drug Abuse, the National Institute on Alcohol Abuse and Addiction, and the Substance Abuse and Mental Health Services Administration. We analyzed the National Survey of Substance Abuse Treatment Services from 2007 through 2017 to determine the percent of facilities having the characteristics of higher quality. We analyzed the percent by state and over time. • We found improvements between 2007 and 2017 on most measures, but performance on several measures remained low. • Most programs reported providing evidence-based behavioral therapies. • Half or fewer facilities offered medications for opioid use disorder; mental health assessments; testing for hepatitis C, HIV, and sexually transmitted diseases; self-help groups; employment assistance; and transportation assistance. • There was significant state-level variation across the measures.

Gli stili APA, Harvard, Vancouver, ISO e altri

Offriamo sconti su tutti i piani premium per gli autori le cui opere sono incluse in raccolte letterarie tematiche. Contattaci per ottenere un codice promozionale unico!